Bionano Genomics - BNGO

Bionano Genomics - BNGO

Postby investar » Wed Jan 15, 2020 4:05 am

IPO sinds August 2018 at 6.2$

Low volume slide down towards 1$ and lower, until a giant volume spike in Oct 19, and jump to 2$

January 2020: for sale at 1.15$ - so a MC of 30m$

https://bionanogenomics.com/

Product: their genome imaging instrument Saphyr
https://bionanogenomics.com/wp-content/ ... re_web.pdf

Catalysts: potential partnership (ILMN/Roche/Pacb etc). ER in March. or headlines like this one:

Breakthrough Findings in Leukemias Presented at ASH 2019 Demonstrate Bionano Saphyr's Potential to Replace All Cytogenetic Methods and Show Additional Clinical Utility
investar
Boss' Left Hand Person
 
Posts: 813
Joined: Tue Feb 16, 2010 11:59 pm

Re: Bionano Genomics - BNGO

Postby investar » Sat Feb 08, 2020 5:48 pm

investar
Boss' Left Hand Person
 
Posts: 813
Joined: Tue Feb 16, 2010 11:59 pm

Re: Bionano Genomics - BNGO

Postby investar » Tue Feb 11, 2020 4:05 am

Excellent news today!

Bionano Genome Imaging Concordant with Traditional Cytogenetics in Landmark Leukemia Study
Mon February 10, 2020 8:00 AM|GlobeNewswire|About: BNGO
GlobeNewswire
SAN DIEGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) announced today that a team led by Dr. Alexander Hoischen from Radboud University Medical Center (RUMC) in the Netherlands reported the results of a successful validation study comparing the performance of Bionano Genomics’ Saphyr® system to traditional cytogenetic methods for the clinical analysis of leukemia genomes. The study, published in bioRxiv, found that Saphyr was 100% concordant with the standard of care for the detection of somatic chromosomal abnormalities.

Structural variants are important for cancer diagnosis, prognosis, and treatment decisions. In a diagnostic set-up, especially for hematological malignancies, the comprehensive analysis of all cytogenetic aberrations requires a combination of techniques, such as karyotyping, fluorescence in situ hybridization and CNV-microarrays. The study set out to test if genome imaging by the Saphyr system could replace these expensive, labor-intensive and time-consuming combination of methods with a single, automated and streamlined workflow.

A total of 48 patient samples with a combination of myeloid and lymphoid leukemias, representative of the most common referrals to the RUMC clinic, were analyzed using standard cytogenetic analysis. All samples had an allele fraction of the pathogenic variants of at least 10%. 37 samples were considered simple and 11 samples were categorized as complex, based on the number of large structural abnormalities. When all 48 samples were subsequently analyzed with Bionano, the team was able to identify all previously reported aberrations. Bionano allowed for a better resolution and a more complete picture of complex aberrations. A complex chromothripsis structure was resolved unambiguously and in other cases, additional fusions were identified, or marker chromosomes of unknown origin were resolved. Generally, genome imaging results were more complete than all three individual previous tests and most likely delivered the true underlying genomic architecture.

The Radboud team pointed out that while the focus of the study was on determining the concordance for diagnostically reported variants, the Bionano technology also found novel variants. They identified 23 potential gene fusions of which only 4 were previously observed. Gene fusions are important prognostic markers in cancer and are routinely targeted for drug development. The Bionano study provided an impressive number of such potential biomarkers.

Alexander Hoischen, Ph.D., Associate Professor, Genomic Technologies and Immuno-Genomics at the Department of Human Genetics of RUMC, comments: “We are positively surprised by the smooth and fast implementation of the Saphyr system in our laboratory. Less than a year after training we now have successfully run more than 150 samples, including the 48 leukemia samples which we now present in this publication. Other samples include novel research findings for unsolved rare disease cases and known cytogenetic abnormalities which may validate the Saphyr system’s use for constitutional aberrations. We are excited about the very high concordance rate between Bionano technology and current standard of care methods and believe that this technology has the potential to revolutionize cytogenetics in the near future.”

Erik Holmlin, Ph.D., CEO of Bionano, commented, “At Bionano, our objective has been to develop the best genome analysis platform to identify structural variation, and it has long been a focus of ours to apply that capability for clinical diagnostics. We have focused on leukemias and lymphomas because the current standard of care consists of a complex combination of various outdated methods, and diagnostic labs, clinicians and patients would be better off if that was transformed. Many attempts have been made to replace cytogenetics using various flavors of short-read and long-read sequencing, and all have failed. This study helps confirm that our Saphyr platform is capable of revolutionizing cytogenetic testing and is the first of many such studies that we believe will demonstrate this utility.”

About Bionano Genomics
Bionano is a life sciences instrumentation company in the genome analysis space. Bionano develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to drive the adoption of digital cytogenetics, which is designed to be a more systematic, streamlined and industrialized form of traditional cytogenetics. The Saphyr system comprises an instrument, chip consumables, reagents and a suite of data analysis tools.

https://www.biorxiv.org/content/10.1101 ... 6.935742v1

I think NOW is a good moment to buy BNGO stocks.
I bought some :-) 1.1$
investar
Boss' Left Hand Person
 
Posts: 813
Joined: Tue Feb 16, 2010 11:59 pm

Re: Bionano Genomics - BNGO

Postby investar » Sat Feb 22, 2020 9:23 pm

No less than 19 oral and poster presenations at the upcoming AGBT event!

https://www.agbt.org/the-general-meeting/

Stock still at 1.11$, made a low of 1.02 though.

Good news can send this stock back to IPO price of 6$, easily...
investar
Boss' Left Hand Person
 
Posts: 813
Joined: Tue Feb 16, 2010 11:59 pm

Re: Bionano Genomics - BNGO

Postby investar » Thu Apr 16, 2020 8:22 am

BNGO did a financing at a huge discount, at 30 cents

So all the shareholders are very much underwater right now.

Only positive about this, is that there is no need for additional capital for the next 2, maybe 3 quarters.
So the stock can maybe recover from the current lows, back towards 1$?

Bionano Genomics to Support Largest Study to Date on COVID-19 Disease Susceptibility

https://ir.bionanogenomics.com/news-rel ... B9tc_xbrEM


The participants will have their genomes analyzed using Next-Generation Sequencing (NGS), and Bionano Genome Imaging. Additionally, the study participants will undergo analysis of their transcriptome to look at gene expression, their metabolome, and a variety of immune markers such as cytokines and T-cell response. The goal of the study is to identify genomic variants that affect the disease, and immune or metabolic variables in the healthier participants that can protect against more severe disease, and to use this knowledge for the development of novel therapies and vaccines.
investar
Boss' Left Hand Person
 
Posts: 813
Joined: Tue Feb 16, 2010 11:59 pm

Re: Bionano Genomics - BNGO

Postby investar » Sat Apr 25, 2020 4:30 am

Buy Recommendation from Oppenheimer, target 1.5$

And new research center is going to use the Saphyr system:
https://markets.businessinsider.com/new ... 1029117177
investar
Boss' Left Hand Person
 
Posts: 813
Joined: Tue Feb 16, 2010 11:59 pm

Re: Bionano Genomics - BNGO

Postby investar » Tue Jun 09, 2020 5:35 am

A new patent was approved: https://todaysfive.com/bionano-genomics-press-release/


Upcoming catalysts:
6/7: ESHG Bio-Conference Event
6/8: Expected Press Release
6/10: Covid-19 Consortium
6/12: webinar

Caveat? Reverse Split maybe. Earnings will not be good.
investar
Boss' Left Hand Person
 
Posts: 813
Joined: Tue Feb 16, 2010 11:59 pm

Re: Bionano Genomics - BNGO

Postby investar » Fri Jun 19, 2020 4:25 am

Results & Update:

116 Saphyrs sold, installed base now 86

No reverse split for another year.
Still enough cash for another Q, maybe 2

I think they should try to sell it to ILMN: with an installed base of 15000+ already, they will probably stay the leader in this field
https://www.twst.com/news/illumina-nasd ... asdaqbngo/


Stock now 54 cents.
investar
Boss' Left Hand Person
 
Posts: 813
Joined: Tue Feb 16, 2010 11:59 pm

Re: Bionano Genomics - BNGO

Postby investar » Wed Dec 02, 2020 5:49 pm

I sold my BNGO during the runup above 1$ in the summer, but now that it is back at 0.5$ I am looking to enter again.

There is some rumor about Quest interest. Pacbio is also expanding the market.

BNGO has been able to publish positive research articles in prestigious scientific journals, like this one
https://www.pnas.org/content/early/2020 ... 72117.full

But the cash burn is still elevated. So the only concern is potential additional dilution or a R/S.
I think they will try to raise the sp first again, hopefully to above 1$, before tackling this concern.
investar
Boss' Left Hand Person
 
Posts: 813
Joined: Tue Feb 16, 2010 11:59 pm

Re: Bionano Genomics - BNGO

Postby investar » Thu Dec 24, 2020 11:47 pm

https://finance.yahoo.com/news/publicat ... 00036.html


Big news: Pacbio has a MC of 5.4 BILLION, BNGO just 110 MILLION (here at 72 cents)

BNGO back above 1$ soon?
investar
Boss' Left Hand Person
 
Posts: 813
Joined: Tue Feb 16, 2010 11:59 pm

Next

Return to A to D

Who is online

Users browsing this forum: No registered users and 6 guests

cron